International Journal of Research in Oncology
Open AccessIs There a Clinical Potential for Antimicrobial Peptides to Serve as a Second Option Treatment for Cancer Therapy? A Commentary/Opinion Paper
Authors: Gerald J Mizejewski.
Abstract
Therapeutic antimicrobial peptides (TAPs) are becoming increasingly more utilized in the field of cancer therapies and treatments. Following the first synthesis of the man-made insulin peptide in the early 1920s, the marketplace for peptides has vastly changed. The use of peptides for nutritional supplements, body building regimens, and biomedical and clinical applications has significantly increased. More recently, the therapeutic utilization of peptides in the clinical cancer arena has employed peptides that instinctively home toward and onto cancer cells as their targeted objective. Such peptides are referred to as antimicrobial “tumor-homing” peptides. The many and varied properties and traits of such peptides include cargo-carrying capabilities to deliver drugs, radionuclides, heavy metals, nanoparticles, and exosomes to targeted cancer cells. This paper will review, discuss, and present the above issues concerning mainly the utilization of antimicrobial tumor-homing peptides for cancer treatment and potentially as therapies for other human disorders.
Editor-in-Chief
View full editorial board →